# A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

> **NCT07014137** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 20 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** ABSK043 single agent

## Key facts

- **NCT ID:** NCT07014137
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014137, "A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07014137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*